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1. Introduction 
Kidney disease secondary to SLE can affects up to 50% of patients with SLE and largely 
mediated by deposition of immune complex in the kidneys (1) (2). 
The clinical diagnosis of lupus nephritis is usually made following a diagnostic kidney 
biopsy in the presence of proteinuria and/or hematouria,positive serology,and extrarenal 
manifestation of SLE. The presence of kidney disease is the most important predictor of 
morbidity and mortality in the patients with SLE. 
Several demographic,serologic,and genetic risk  factors are associated with an increased risk 
for developing kidney disease. Patient with lupus nephritis are more likely than SLE 
patients without kidney involvement to have a family history of SLE,anemia,high anti-
dsDNA antibody titer,and hypocomplementemia. Children with SLE develop nephritis 
more frequently than adults and so do males.  
2. Pathogenesis 
Autoimmunity plays a major role in the pathogenesis of lupus nephritis. The immunologic 
mechanisms include production of autoantibodies directed against nuclear elements.  
These autoantibodies form pathogenic immune complexes. Deposition of these immune 
deposits in the kidneys initiates an inflammatory response by activating the complement 
cascade and recruiting inflammatory cells that can subsequently be observed on biopsy 
specimens. 
Glomerular thrombosis is another mechanism that may play a role in pathogenesis of lupus 
nephritis, mainly in patients with antiphospholipid antibody syndrome, and is believed to 
be the result of antibodies directed against negatively charged phospholipid-protein 
complexes. 
3. Symptoms and signs of lupus nephritis 
Clinically lupus nephritis varies in its expression mild ,asymptomatic  proteinuria to an 
overt nephrotic syndrome or acute nephritis associated with rapidly progressive azotemia. 
Glomerulonephritis is uncommonly the sentinel manifestation of SLE.  
The key challenge for the clinician  is to detect clinically significant lupus nephritis befor the 
appearance of the overt disease. 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
244 
Patients can present with proteinuria during regular follow up. Hypertention is more 
common in patient with diffuse prolifrative lupus nephritis compared with focal prolifrative 
lupus nephritis or membranous lupus nephritis. Edema is an other presentation of lupus 
nephritis. 
4. Prognostic factors 
Different factors have been identified to predict the prognosis of lupus nephritis (3). 
Histological factors: 
 Histological class IV(diffuse proliferative LN) 
 High activity and chronicity on Biopsy 
 Crescents and interstitial fibrosis 
 Segmental necrotizing lesion 
Clinical Predictors: 
 Hypertension            
 Anemia         
 high baseline creatinine     
 high  base line proteinuria                    
 Delay in therapy 
Epidemiological Predictors  
 Low  socioeconomic  status                        
 African  American Race 
5. Classification of Lupus Nephritis (LN) 
Types of lupus nephritis  
Renal biopsy is essential for the staging the type and the severity of lupus nephritis  and 
planning the treatment. 
Indication of renal biopsy 
Renal  biopsy is indicated  in patients who have one or both of the following clinical 
manifestations: 
 Protein excretion greater than 500 mg/day. 
 An active urinary sediment with hematuria (five or more red blood cells per high 
power field, most of which are dysmorphic) and often pyuria and cellular casts. The 
urine may be contaminated with vaginal blood in menstruating women. Red cells from 
this source are not dysmorphic. 
Lupus patients who have an inactive sediment and less than 500 mg/day of proteinuria are 
unlikely to have focal or diffuse proliferative or membranous lupus nephritis (LN). They 
may have minimal mesangial or mesangial proliferative disease, neither of which requires 
immunosuppressive treatment. 
Such patients should be followed for evidence of progressive disease such as increasing 
proteinuria, emergence of an active sediment, and/or an increase in serum creatinine. These 
manifestations suggest transformation to a more severe lesion and warrant renal biopsy. 
In patients with an inactive sediment and less than 500 mg/day of proteinuria, it is advisable 
to do a urinalysis every three to six months for three years; every three months is preferred in 
patients with anti-double-stranded DNA antibodies and/or hypocomplementemia. 
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The initial classification is WHO that have been modified in 1982 and 1995(4).The most 
recent classification is ISN/RPS 2004(international society of nephrology and renal 
pathology society) (5). 
 
DESIGNATION DESCRIPTION 
Class I: Minimal 
mesangial LGN 
Near-normal glomeruli by LM; mesangial deposits are present by IF 
and/or EM 
Class II: Mesangial 
proliferative LGN 
Mesangial hypercellularity and matrix expansion, with mesangial 
deposits by IF and EM 
Class III: Focal LGN 
<50% of glomeruli display active or inactive segmental (<50% of the 
tuft) or global (>50% of the tuft) endocapillary proliferation or 
sclerosis; predominantly mesangial and subendothelial deposits are 
present on IF and EM 
Class IV: Diffuse 
LGN 
>50% of glomeruli have endocapillary or extracapillary 
glomerulonephritis;predominantly mesangial and  
subendothelial deposits are present on IF and EM; two subsets  
are defined 
Class IV-S: 
Segmental diffuse 
LGN 
>50% of affected glomeruli have segmental lesions 
Class IV-G: Global 
diffuse LGN 
>50% of affected glomeruli have global lesions 
Class V: 
Membranous  
LGN 
Capillary loop thickening in association with predominantly 
subepithelial deposits by IF and EM 
Class VI: Advanced 
sclerosis 
>90% of glomeruli are obsolescent, with substantial activity in 
remaining glomeruli 
Table 1. International Society of Nephrology—Renal Pathology Society, 2004 Classification 
of Lupus Glomerulonephritis  
Characteristic clinical features of patients with the various classes of pathology can be 
summarized as follows:  
 Class I, Minimal mesangial lupus glomerulonephritis (LGN)—normal urine or 
microscopic hematuria 
 Class II, Mesangial proliferative LGN—microscopic hematuria and/or low-grade 
proteinuria 
 Class III, Focal proliferative LGN—nephritic urine sediment and subnephrotic 
proteinuria 
 Class IV, Diffuse proliferative LGN—nephritic and nephrotic syndromes, hypertension, 
azotemia 
 Class V, Membranous LGN—nephrotic syndrome 
 Class VI, Sclerosing disease—hypertension and reduced kidney function 
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EM, electron microscopy; IF, immunofluorescence; LGN, lupus glomerulonephritis; LM, light  
microscopy  
Fig. 1. Light microscopic changes in lupus glomerulonephritis (LGN). A,  
Segmental proliferative LGN. The glomerulus shows a discrete segmental lesion  
with karyorrhexis and necrosis (gold arrows); the remaining capillary loops are patent  
with only mild mesangial expansion (hematoxylin and eosin stain). B, Global proliferative 
LGN with an extracapillary cellular crescent (asterisk); the integrity of the glomerular  
tuft is compromised by proliferation and thickening of the capillary loops (hematoxylin  
and eosin stain). C, Pure global proliferative LGN (hematoxylin and eosin stain).  
D, Membranous LGN; capillary loops are uniformly thickened (hematoxylin and  
eosin stain).  
6. Treatment of lupus nephritis 
Treatment depends mainly on the clinical presentation and the pathological classification of 
LN. The treatment usually consists of two phases, the induction phase and the maintenance 
phase. The total duration of treatment around two years but it can varies based on the 
clinical response. But all patients need to be on non-immunosuppressive therapy. 
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Non-immunosuprressive therapy 
Angiotensin inhibition – Administration of an angiotensin converting enzyme (ACE) 
inhibitor or an angiotensin II receptor blocker (ARB) is recommended in virtually all 
patients with proteinuric chronic kidney disease, since such therapy may significantly 
reduce the rate of disease progression, acting at least in part by lowering the intraglomerular 
pressure. The recommended goal for protein excretion is at least a 60 percent reduction from 
the baseline value and optimally less than 500 to 1000 mg/day. Patients with baseline 
protein excretion below 500 mg/day do not appear to benefit from angiotensin 
inhibition.(21). 
 
 
Fig. 2. Ultrastructural changes in lupus glomerulonephritis (LGN). A, Mesangial proliferative 
LGN; electron-dense deposits corresponding to immune complexes are concentrated in 
mesangial region (red arrows). B and C, Continuum of subendothelial and intraluminal 
electron-dense deposits characteristic of proliferative forms of LGN (red arrows). D, 
Subepithelial electron-dense deposits characteristic of membranous LGN (red arrows).  
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Blood pressure control – The goal blood pressure in patients with any form of proteinuric 
chronic kidney disease is less than 130/80 mmHg, if the proteinuria is more than 3.5g/day 
the target is less than 125/70. Reaching  this goal can slow the progression of proteinuric 
chronic kidney disease. It may also provide cardiovascular protection, since chronic kidney 
disease is associated with a marked increase in cardiovascular risk. BP control through 
rennin angiotensin aldosterone(RAAS) blockade is a cornerstone of conservative therapy in 
lupus nephritis. The RAAS, and its pharmacologic blockade, may play a role in the 
pathogenesis and prognosis of SLE independent of its effects on systemic BP and glomerular 
hemodynamics. A number of animal studies have highlighted the inflammatory 
components of the RAAS and the potential  benefits of RAAS blockade in reducing or 
eliminating this inflammation in lupus nephritis (22). 
Lipid lowering – Hyperlipidemia, with often dramatic elevations in the serum cholesterol 
concentration, is commonly present in patients with nephrotic syndrome. Although control 
of serum LDL cholesterol is the main indication for statin therapy, there is some evidence in 
patients with chronic kidney disease that it may also slow the progression of the underlying 
renal disease (22). 
7. Immunosuppressive therapy 
Different immunosuppressive  medication can be used as induction and/or maintenance 
therapy as follows: 
 
induction maintaince 
cyclophosphamide cyclophosphamide 
Mycophenolate mofetil Mycophenolate mofetil 
Rituximab Rituximab 
Steroids Steroids 
 Cyclosporine 
 Azathioprine 
 
1. Steroids  
During the induction phase Methylprednisolone in doses of 7mg/kg/day as intravenous 
pulse therapy for three days followed by 1 mg/kg/day for 4-6 weeks to be tapered during 
the maintenance phase   slowly according to the clinical response (6).it is usually used in 
combination with other drugs. 
2. Cyclophosphamide  
The most studied in lupus nephritis. The data for using Cyclophosphamide is coming 
mainly from two major randomized control trial. The first one is the National Institutes of 
Health (NIH) study(6), which used cyclophsphamide  as intravenous  monthly  doses for 6 
consecutive months, starting at a dose of 0.5g/m2 body surface not to exceed 1g/m2. After 
the first 6 months .pulse cyclophosphamide is given every 3 months for a total of 24 months. 
The second trial is EURO Lupus trial (7) (8).intravenous cyclophosphamide is given every 2 
weeks in a fixed dose of 500 mg for 6 doses,  followed by Azathioprine  (2mg/kg/day) to 
finish 30 months of treatment. 
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The downside of treatment with cyclophosphamide is the side effect profile associated with 
it including leucopenia, increase  risk of infection, hemorrhagic cystitis ,hair loss and 
increase risk of malignancy. 
Both regimen were equally effective in various renal and extra-renal outcomes. The low 
dose regimen(Euro-lupus) had less toxicity with significantly less sever and total infections 
as  a complication of treatment(8). 
During the treatment with cyclophsphamide  physician need to monitor the patient with 
biweekly WBC count during the first six months them monthly and adjust the dose if the 
WBC count drop below 3000 mm2. 
Mycophenolate mofetil l(MMF) 
The active component of MMF, mycophenolic acid, is an inhibitor of inosine 5'-
monophosphate dehydrogenase, the rate-controlling enzyme in de novo biosynthesis of 
guanosine triphosphate, used by antigen-activated B cells and T cells. Mycophenolic acid 
exhibits a selective antiproliferative effect on lymphocytes with anti-inflammatory effects 
and a profound effect on autoantibody production by B cells. 
Because of its favorable safety profile, there has been great interest in the use of 
Mycophenolate mofet(MMF) as both induction and maintenance therapy(9)(10)(16). Since 
2000 two controlled trials comparing induction therapy with MMF versus 
cyclophosphamide have indicated comparable rates of renal remission and short term renal 
survival but fewer side effects in patients treated with MMF. The best data are from 
international trial (ALMS) that compared MMF in a dose of 3g/day as induction therapy for 
six months  with monthly intravenous Cyclophosphamide(IVC) for six doses (11). Overall 
response rates similar with MMF and IVC in all renal and non-renal parameters. In this trial 
MMF in a dose of 1g twice daily for 36 months was superior to Azathioprine in 
2mg/kg/day as maintenance therapy.  
MMF can be used in a dose of 3g/day in divided dose for 6 months as induction therapy 
followed by 1g twice daily for 36 months as maintenance therapy.  
Cyclosporine (CSA) 
The available data suggest that CSA may be a useful drug in patients with lupus nephritis 
showing persistent sever proteinuria after induction therapy or intolerance to other 
immunosuppressive drugs (12). 
Azathioprine(AZA) 
The role of AZA is much less established as induction therapy. The available data support 
the use of AZA as maintenance therapy for 24-30 months (7) (12). 
preferred in women who are in complete remission and want to become pregnant. 
Cyclosporine is an alternative if azathioprine is not tolerated. MMF has a boxed  
warning because of an increased risk of congenital malformations and spontaneous 
abortion.  
Rituximab  
An anti-CD20 monoclonal antibody that depletes B cells, is useful in inducucing remissions 
in some patients. Currently rituximab is used for refractory or non-responder cases, alone or 
in combination with other immunosuppressive agents (13)(17) 
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Plasmapheresis 
Randomized trials showed no add benefit value of plasmapheresis to immunosuppressive 
therapy in patient with lupus nephritis (14) (15). However, plasmapheresis may have a role 
in selected patients, such as those with severe crescentic LN who require dialysis (especially 
those with concomitant ANCA, extrapolating from the MEPEX trial of patients with 
Wegener's granulomatosis) or those with proliferative LN and thrombotic 
thrombocytopenic purpura with antiphospholipid antibodies. 
The above mentioned lines of treatment usually indicated for class three and four. 
Treatment of membranous lupus nephritis still controversial. Most of the clinical trial 
included patients with focal or diffuse proliferative lupus nephritis. 
In general patients with membranous lupus nephritis who have normal renal function and 
subnephrotic proteinuria may not require intensive immunosuppressant while patient with 
high grade nephrotic  syndrome or abnormal renal function or mixed membranous and 
proliferative lesions on biopsy which may be present at diagnosis or develop later need to 
be treated with immunosuppressant. 
The only randomized trial limited to patients with pure lupus MN, the National Institutes  
of Health (NIH) trial, showed equivalent efficacy with cyclophosphamide plus 
glucocorticoids and cyclosporine plus glucocorticoids [18]. There were trends with 
cyclosporine toward higher rates of both remission (83 versus 60 percent at one year) and of 
relapse after the cessation of therapy (60 percent within 36 months versus 20 percent within 
50 months. 
A randomized trial (ALMS) compared MMF with cyclophosphamide in 370 patients  
with LN, including 60 with pure membranous LN [11]. The primary outcome was a 
prespecified reduction in the urine protein-to-creatinine ratio to less than 3 or by at least  
50 percent. Secondary outcomes included stabilization or improvement of the serum 
creatinine, reduction of protein excretion to less than 0.5 g/day, and attainment of inactive 
urinary sediment. At 24 weeks, there was no difference in the two groups in the percentage  
of patients with pure membranous LN who achieved either the primary or secondary 
outcome. 
8. In summary  
1. lupus nephritis stage ІІІ and ІV with active disease( high creatinine and/or proteinuria 
> 500 mg/day and/or active sediment: should be treated with cyclophosphamide 
intravenous as monthly dose for six months as induction therapy followed by 
cyclophosphamide intravenous every 3 months to finish 24 months.  
2. The other approach to treat stage 3 and 4 lupus nephritis is to use cyclophosphamide 
intravenous in a fixed dose 500 mg  every 2 weeks for six doses as induction therapy 
followed by MMF in a dose of 1 mg orally twice daily for 36 months which has been 
superior to Azathioprine as maintenance therapy. This approach is preferable to the 
former approach because the risk of side effect is much less. 
3. If the patient can not take cyclophosphamide  or prefer not to, MMF can be used in a 
dose of 3g/day in divided dose for six months as induction therapy followed by MMF 
in a dose of 1-2 g/day for 36 months as maintenance dose. 
4. For stage 5 lupus nephritis with active disease(nephritic range proteinuria,active 
sediment and/or abnormal renal function, can be treated with oral cyclosporine in a 
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dose of 5mg/kg /day in divided doses but the dose need to be adjusted if the creatinine 
is rising. this treatment need to be continued for one year. 
Intra venous Cyclophosphamide can be used (0.5-1.0g/m2) given every other month for 
one year. 
If patient can not tolerate cyclosporine or cyclophosphamide,MMF can be used as it was 
beneficial in ALMS trial. It can be used in dose of 3g/day for 6 months then to be 
reduced to 1-2g/day.  
9. Criteria for clinical reemission  
Most of the clinical trials defined complete remission can be defined by the following 
criteria, 
1. Inactive urinary sediment   defined as ≤5 red blood cells per high power field, ≤5 white 
blood cells per high power field, a reading of 0 to 1+ on the urine dipstick for heme, and 
no red cell casts. 
2. Normalization of the serum creatinine and protein excretion below 500 mg/day. 
Partial remission can be defined by reduction of proteinuria by 50% or more. 
10. Kidney transplantation in patient with lupus nephritis 
If patient with lupus nephritis progress to ESRD and require dialysis, data suggest that renal 
transplant has better outcome than dialysis in such patients. (19) 
Long-term patient and graft survivals were similar in SLE and non-SLE renal  
transplant recipients. The risk for thrombotic complications was greater among SLE  
patients (19). 
Patients need to be clinically and serologically inactive at the time of transplant.  
The rate of clinically recurrent disease in the renal transplant of 2.0 to 9.0 percent in  
patients with lupus nephritis, which is thought to reflect, diminished immunologic  
activity (20). The incidence of recurrent symptoms of systemic lupus was also low at 5.7 
percent. 
11. Experimental therapy 
Several studies involving novel therapeutic agents for lupus nephritis are underway. The 
agents being evaluated in these studies are summarized in Table 24-3. The Web site 
www.clinicaltrials.gov is a potentially useful resource in searching for studies that may be 
recruiting patients, along with information about eligibility and exclusion criteria. 
12. Prognosis 
The prognosis of class III and IV proliferative lupus nephritis has improved, from a 5-year 
renal survival rate of less than 20% during the period 1960-1980 to a rate of more than 80% 
during 1980-2000. This improvement in prognosis has been ascribed mostly to increasing 
use of cyclophosphamide. Although preliminary data based on achievement of renal 
remission suggest that mycophenolate mofetil may have comparable benefits, it remains to 
be established whether mycophenolate mofetil will achieve comparable long-term renal 
survival. 
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Monoclonal Antibodies (Targets) 
Rituximab (CD20, B cells)[∗ † ‡] 
Epratuzumab (CD22, B cells)[∗] 
MEDI-545 (interferon-α)[‡] 
Belimumab (BLyS cytokine)[‡] 
Tocilizumab (interleukin-6 receptor)[‡] 
Infliximab (tumor necrosis factor)[∗ ‡] 
Costimulation Inhibitors 
CTLA4-Ig, abatacept, belatacept (CD80/86)[‡] 
Tolerogens 
Abetimus, LJP-394 (anti-DNA)[‡] 
Hematopoietic stem cell transplants ∗  Case reports. 
†  Case series. 
‡  Ongoing clinical trials. 
Table 2. Experimental Therapies for Systemic Lupus Erythematosus and Lupus Nephritis 
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